Recent Updates
Recently added Catalysts
IMNM Positive Sentiment

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Friday, November 6, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Immunome, Inc. announced the grant of inducement awards on November 2, 2026. The Compensation Committee awarded non-statutory stock options for 206,700 shares and 103,350 restricted stock units. This move aims to attract and retain talent while complying with Nasdaq listing rules.

Market Sentiment Analysis

POSITIVE FACTORS

  • Immunome granted stock options and RSUs to attract talent.
  • The awards align with Nasdaq listing requirements.
  • The company is focused on developing innovative cancer therapies.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+27%
120-day peak, hindsight
Typical move
28.8%
average across 3 past catalysts
Cash runway
~22 mo
Low dilution risk
Lead asset
IM-1021
Phase 1 · Solid Malignancies

Full Press Release Details

BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (the “Company”) (Nasdaq: IMNM), a clinical-stage targeted oncology company focused on developing first-in-class and best-in-class cancer therapies, announced today that on November 2, 2026, the Compensation Committee of the Company’s Board of Directors (the “Compensation Committee”) granted inducement awards consisting of non-statutory stock options to purchase an aggregate of 206,700 shares of common stock and 103,350 restricted stock units (“RSU

Frequently Asked Questions

What inducement awards did Immunome grant?

Immunome granted stock options for 206,700 shares and 103,350 RSUs.

When were the inducement awards granted?

The awards were granted on November 2, 2026.

Why did Immunome grant these awards?

The awards aim to attract and retain talent in compliance with Nasdaq rules.

What type of stock options were granted?

The options granted are non-statutory stock options.

ShareAdd on Google
Tags: IMNM Immunome stock options restricted stock units cancer therapies Nasdaq
Last updated: Nov 6, 2026

Biotech snapshot

Cash runway
$520M liquidity · $21M/mo burn
~22 mo
Low dilution risk
Lead asset
IM-1021Phase 1
Solid Malignancies →

Catalyst track record

+27%
best trade around IMNM's most recent catalyst

Peak hindsight return over a 120-day window, across 3 tracked FDA/PDUFA catalysts for IMNM.

See every catalyst's timing & PoA →